GMDC and J&J showcase diabetes opportunity in latest infocast
COLORADO SPRINGS, Colo. – GMDC on Thursday hosted Sally Manoufar, senior manager Health & Wellness at Johnson & Johnson, and Sara Bender, senior channel marketing manager at Johnson & Johnson, to learn about Johnson & Johnson's diabetes front-end solution as part of the group's lunchtime Infocast Event.
Diabetes as an epidemic in North America can, and is, providing opportunities for retailers to become a centralized health and wellness destination for consumers, GMDC noted. And technology is paving the way for consumers to manage their diabetes at home through a surge of innovation and inventive products that appeal to those shoppers who “self-care."
First, the opportunity surrounding patients with diabetes is significant. Diabetes patients are spending between $1,000 and $2,500 each year on diabetes supplies alone, Manoufar noted. "If you go beyond that, on average [patients with diabetes] have 2.6 additional illnesses on top of their diabetes," she said. "That could be another $1,000 to $3,000 per year in annual prescription costs." According to J&J research, the front-end basket of a diabetes patient is five times larger than that of a patient who doesn't have diabetes.
J&J's OneTouch team has recently invested in a solution called KnowMyCoPay, which empowers diabetes patients and their pharmaicsts with a tool to help them best manage their diabetes spend.
Another helpful disease management tool is the OneTouch app. "We really believe this is the future of diabetes management," Bender shared. "It's not just managing the number through a meter but managing the data through digitally-based technologies."
Bayer brings Aleve Direct Therapy to TENS device space
WHIPPANY, N.J. – Bayer on Thursday joined the number of companies fielding a TENS pain relief device with Aleve Direct Therapy.
"For people suffering from lower back pain the availability of the Aleve Direct Therapy TENS Device is good news. The device provides drug-free, deep penetrating lower-back pain relief, without a prescription," stated Fred Duchin, VP marketing Analgesics of Bayer's Cough & Cold, Cardiovascular, Consumer Health Division.
Aleve Direct Therapy is indicated for the temporary relief of pain associated with sore and aching muscles in the lower back due to strain from exercise or normal household and work activities. Aleve Direct Therapy is regulated as a Class II medical device and was cleared by the U.S. Food and Drug Administration.
"Aleve Direct Therapy puts controllable TENS technology in consumers hands without having to visit the doctor. It provides high intensity of power and its wireless remote control makes it easy to adjust the power of intensity to fit the user's needs," said Andre Schmidt, VP, US Medical Affairs, Consumer Health Division, Bayer.
Omron releases open API, invites mobile app developers to collaborate
LAKE FOREST, Ill. – Omron Healthcare on Thursday announced the release of the Omron Application Program Interface and invited mobile app developers to participate in open-source collaboration.
"Omron's mission is a world with zero heart attacks and strokes," stated Ranndy Kellogg, president and CEO Omron Healthcare. "We know that in a digital age, achieving that mission means making technology for heart health more mobile, more connected and more responsive to consumer lifestyles than ever before. By opening our API, we invite developers to help change behaviors to promote heart health."
With the open API, developers can connect to and interact with Omron APIs using HTTPS-based request/response scenario-supported programming language and platforms. To build a productive environment of collaboration, developers are now able to access and integrate valuable, multidimensional data on market and technology advancements from Omron.
In order to access the API, end users must create an account for Omron Wellness, which will then send data to any partner app connected through the API via a cloud data transfer.
Omron's open API for native and client-side applications features OAuth 2.0 protocol, Open ID Connect, secure communication between platforms, free access to Omron's staging and production environments and on-demand polling and pulling of data.
The API will be compatible with the following Omron products: BP761N, BP761CANN, BP786N, BP786CANN, BP653, BP654, HJ-327Tbulk, HJ-323U, HJ-342U, HJ-322U and HJ-720ITC.
The open API will be conducted in accordance with Omron's privacy policies and protections, the company stated.